For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2011, including the Forward-Looking Statement sections therein, and other filings with the U.S. Securities and Exchange Commission.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com. CAMBREX CORPORATIONStatements of Profit and LossFor the Quarters Ended March 31, 2012 and 2011(in thousands, except per-share data)20122011% of% ofAmountSalesAmountSalesGross Sales
61,654Commissions, Allowances and Rebates535291Net Sales70,02461,363Other204(778)Net Revenues70,22860,585Cost of Goods Sold47,80067.7%43,13070.0%Gross Profit22,42831.8%17,45528.3%Operating ExpensesSelling, General and Administrative Expenses9,96014.1%9,08814.7%Research and Development Expenses2,3583.3%3,0605.0%Total Operating Expenses12,31817.5%12,14819.7%Operating Profit10,11014.3%5,3078.6%Other Expenses/(Income):Interest Expense, net651573Other Expenses/(Income), net8(3)Equity in Losses of Partially-Owned Affiliates208364Income Before Income Taxes9,24313.1%4,3737.1%Provision for Income Taxes2,2051,518Income from Continuing Operations
|SOURCE Cambrex Corporation|
Copyright©2010 PR Newswire.
All rights reserved